Zhitong Finance APP learned that $AIM VACCINE (06660.HK)$Rising by more than 38%, up more than 80% over the past two trading days. As of the press time, it rose by 36.01%, to 7.78 Hong Kong dollars, with a turnover of 43.3962 million Hong Kong dollars.
On the news front, recently, Aimi Vaccines announced its participation in CPHI Milan, the world's largest pharmaceutical industry professional exhibition, to be held in Milan, Italy from October 8th to 10th, 2024. It is reported that Aimi has 8 commercially available vaccines, 21 vaccines in the pipeline, covering the top ten vaccine varieties globally. The commercialized products have long held a leading market position, with sales covering all 31 provinces, autonomous regions, and municipalities in China, reaching over 2000 districts and counties' disease control centers.
By the end of the first half of 2024, the company's three heavyweight l products, a 13-valent pneumococcal conjugate vaccine, a serum-free iterative rabies vaccine, and a 23-valent pneumococcal polysaccharide vaccine, are entering the final stage before listing. In addition, the company's two heavyweight l products, mRNA RSV (respiratory syncytial virus) vaccine and mRNA herpes zoster vaccine, have been submitted for clinical trial applications in both China and the United States.
